Universal vs selective tranexamic acid use for preventing blood loss after cesarean delivery: a reanalysis of the TRAAP-2 trial - 09/01/26
Doi : 10.1016/j.ajog.2025.04.047
Thomas Ferté, MD
CHU Bordeaux, Public Health Department, Clinical Epidemiology Unit, Bordeaux, France
University Bordeaux, ISPED, INSERM, U1219-Bordeaux Population Health Research Centre, Bordeaux, France
Antoine Benard, MD, PhD
CHU Bordeaux, Public Health Department, Clinical Epidemiology Unit, Bordeaux, France
University Bordeaux, ISPED, INSERM, U1219-Bordeaux Population Health Research Centre, Bordeaux, France
Kilian Trin, MD
CHU Bordeaux, Public Health Department, Clinical Epidemiology Unit, Bordeaux, France
University Bordeaux, ISPED, INSERM, U1219-Bordeaux Population Health Research Centre, Bordeaux, France
Hugo Madar, MD
Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France
Catherine Deneux-Tharaux, MD, PhD
Université de Paris, CRESS, Obstetrical, Perinatal and Paediatric Epidemiology Research Team, EPOPé, INSERM, INRA, Paris, France
Loïc Sentilhes, MD, PhD 
Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France
On behalf
the TRAAP2 study group (eAppendix 1 in the Supplement) ∗
Key words : cesarean, postpartum hemorrhage, subgroup, tranexamic acid, treatment effect heterogeneity
Plan
| L.S. has performed consultancy work; has been a lecturer for Ferring Laboratories, GlaxoSmithKline, and Bayer; and has been a lecturer for Norgine in the previous 3 years. The other authors report no conflict of interest. |
|
| The TRAAP-2 trial was supported by the French Ministry of Health (PHRC-15-0011). The funder had no role in the design and conduct of the TRAAP-2 trial. This analysis has not received any specific funding. |
|
| Clinical trial identification number: NCT03431805 ( NCT03431805 ). |
|
| Data sharing requests will be considered by the management group upon written request to the corresponding author. Deidentified participant data or other prespecified data will be available subject to a written proposal and a signed data sharing agreement. |
© 2025
Elsevier Inc. Tous droits réservés.
Vol 233 - N° 6S
P. S310-S313 - janvier 2026 Retour au numéro
Article précédent
- Hemostatic resuscitation: blood product replacement during cesarean delivery
- Luis D. Pacheco, Michaela K. Farber, Juliana Gevaerd Martins, Chasey I. Omere, Amir A. Shamshirsaz, Sean G. Yates
- Management of immediate and delayed postpartum hemorrhage with cesarean delivery
- Hugo Madar, Alizée Froeliger, Gilles Kayem, Hanane Bouchghoul, Loïc Sentilhes
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?